Cardiology

Top Story

REVEAL: Anacetrapib plus atorvastatin reduces coronary events in high-risk patients

June 27, 2017

Merck announced anacetrapib, its investigational cholesteryl ester transfer protein inhibitor, significantly reduced major coronary events vs. placebo when added to statin therapy in the REVEAL trial.

The randomized, double blind, placebo-controlled clinical trial was designed to assess the efficacy and safety of adding anacetrapib to atorvastatin in approximately 30,000 patients at high risk for cardiac events despite effective LDL lowering, according to a press release from the company.

In the Journals

ITALIC: Results for 6-month, 24-month DAPT similar 2 years after DES implantation

June 27, 2017
In the Journals

Platelet reactivity not linked to clinical outcomes after PCI in patients with PAD

June 27, 2017
Peripheral artery disease was linked to an increased risk for adverse events after PCI with a drug-eluting stent, but this association was not directly affected by high…
In the JournalsPerspective

Pregnancy complications increase risk for premature CHD in adults

June 27, 2017
Babies born to mothers with pregnancy complications had an increased risk for premature CHD as young adults, according to a study in Heart Asia. “These recent…

Texas Children’s Hospital ranked No. 1 for pediatric cardiology, heart surgery

June 27, 2017
Texas Children’s Hospital has been named at the best hospital for pediatric cardiology and heart surgery by U.S. News & World Report. “This ranking is…
More News Headlines »
Advertisement
Advertisement